Human Genetics

, Volume 111, Issue 2, pp 166–171

Androgen receptor CAG polymorphism and prostate cancer risk

  • Nina Mononen
  • Tarja Ikonen
  • Ville Autio
  • Annika Rökman
  • Mika P. Matikainen
  • Teuvo L. Tammela
  • Olli-P. Kallioniemi
  • Pasi A. Koivisto
  • Johanna Schleutker
Original Investigation

Abstract.

Recent studies have suggested that polymorphisms of the androgen receptor gene (AR) may influence the risk of prostate cancer (PC) development and progression. Here, we analyzed the length of the CAG repeat of the AR gene in 1363 individuals, including patients with PC, benign prostate hyperplasia (BPH), and population controls. There was a tendency for short CAG repeats to be associated with PC. The Odds Ratio (OR) for PC was 1.47 (P=0.05) when individuals with short CAG repeats (≤18) were compared with those having long repeats (>18). CAG repeat length was not significantly associated with family history, disease stage, grade, age at diagnosis, prostate-specific antigen (PSA) level at diagnosis, or prognosis of the patients. Unexpectedly, short CAG repeats were significantly less common in patients with BPH compared with controls (OR=0.47, P=0.03). Our results suggest that the CAG polymorphism of the AR gene is unlikely to have a major role in the development or progression of PC in the Finnish population. The association of CAG repeats with the risk of BPH warrants further study.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag 2002

Authors and Affiliations

  • Nina Mononen
    • 1
  • Tarja Ikonen
    • 1
  • Ville Autio
    • 3
  • Annika Rökman
    • 1
  • Mika P. Matikainen
    • 1
  • Teuvo L. Tammela
    • 4
  • Olli-P. Kallioniemi
    • 5
  • Pasi A. Koivisto
    • 1
  • Johanna Schleutker
    • 1
  1. 1.Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, Lenkkeilijankatu 6, 33520 Tampere, FinlandFinland
  2. 2.Department of Clinical Genetics, Tampere University Hospital, P.O. Box 2000, 33521 Tampere, FinlandFinland
  3. 3.Tampere School of Public Health, University of Tampere, 33014 Tampere, FinlandFinland
  4. 4.Department of Urology, Tampere University Hospital and Medical School, University of Tampere, 33521 Tampere, FinlandFinland
  5. 5.Cancer Genetics Branch, NHGRI, NIH, Bethesda, MD 20892, USAUSA

Personalised recommendations